Neximmune, Inc. Financials
This page shows Neximmune, Inc. (NEXI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Neximmune, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Neximmune, Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Neximmune, Inc.'s current ratio of 1.06 is below the typical benchmark, resulting in a score of 16/100. However, the company holds substantial cash reserves (63% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Neximmune, Inc. generates a -921.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -193.5% the prior year.
Neximmune, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Neximmune, Inc. generates $0.97 in operating cash flow (-$31.4M OCF vs -$32.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Neximmune, Inc.'s EBITDA was -$31.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 48.5% from the prior year.
Neximmune, Inc. reported -$32.3M in net income in fiscal year 2023. This represents an increase of 48.3% from the prior year.
Neximmune, Inc. earned $-30.82 per diluted share (EPS) in fiscal year 2023. This represents an increase of 52.5% from the prior year.
Cash & Balance Sheet
Neximmune, Inc. generated -$31.5M in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 40.0% from the prior year.
Neximmune, Inc. held $3.2M in cash against $0 in long-term debt as of fiscal year 2023.
Neximmune, Inc. had 1M shares outstanding in fiscal year 2023. This represents an increase of 2.2% from the prior year.
Margins & Returns
Neximmune, Inc.'s ROE was -921.6% in fiscal year 2023, measuring profit generated per dollar of shareholder equity. This is down 728.1 percentage points from the prior year.
Capital Allocation
Neximmune, Inc. invested $19.3M in research and development in fiscal year 2023. This represents a decrease of 59.1% from the prior year.
Neximmune, Inc. invested $49K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 96.1% from the prior year.
NEXI Income Statement
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $647K-13.0% | $744K | N/A | $6.0M+23.1% | $4.9M-20.3% | $6.1M | N/A | $11.1M |
| SG&A Expenses | $2.1M+3.4% | $2.0M | N/A | $4.0M+37.4% | $2.9M-21.5% | $3.7M | N/A | $3.7M |
| Operating Income | -$3.5M-27.3% | -$2.8M | N/A | -$10.0M-28.4% | -$7.8M+20.8% | -$9.8M | N/A | -$14.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$2.3M+24.4% | -$3.1M | N/A | -$9.9M-30.2% | -$7.6M+20.9% | -$9.6M | N/A | -$14.7M |
| EPS (Diluted) | $-1.69+31.3% | $-2.46 | N/A | $-9.40 | $-7.25+20.9% | $-9.17 | N/A | $-15.09 |
NEXI Balance Sheet
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.9M-34.8% | $9.0M+4.6% | $8.6M-41.0% | $14.6M-38.0% | $23.5M-23.4% | $30.7M-28.8% | $43.1M-25.3% | $57.7M |
| Current Assets | $3.1M-48.2% | $6.0M+11.9% | $5.4M-47.7% | $10.3M-44.2% | $18.5M-27.2% | $25.4M-32.0% | $37.4M-28.1% | $52.0M |
| Cash & Equivalents | $2.4M-45.6% | $4.5M+39.0% | $3.2M-64.4% | $9.0M-44.7% | $16.3M-27.0% | $22.3M-35.6% | $34.6M-24.5% | $45.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.9M-18.0% | $6.0M+18.5% | $5.1M-19.4% | $6.3M-2.5% | $6.5M-8.7% | $7.1M-34.1% | $10.8M+8.0% | $10.0M |
| Current Liabilities | $4.7M+2.2% | $4.6M-8.8% | $5.1M-18.1% | $6.2M-1.0% | $6.3M-7.6% | $6.8M-34.3% | $10.3M+10.0% | $9.4M |
| Long-Term Debt | N/A | N/A | $0 | N/A | N/A | N/A | $0 | N/A |
| Total Equity | $696K-74.6% | $2.7M-21.9% | $3.5M-57.5% | $8.3M-51.5% | $17.0M-27.9% | $23.6M-27.0% | $32.3M-32.3% | $47.7M |
| Retained Earnings | -$228.0M-1.0% | -$225.7M-1.4% | -$222.6M-2.5% | -$217.2M-4.8% | -$207.4M-3.8% | -$199.8M-5.0% | -$190.2M-9.7% | -$173.4M |
NEXI Cash Flow Statement
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M+14.2% | -$2.4M+58.6% | -$5.8M+19.9% | -$7.3M-20.8% | -$6.0M+50.9% | -$12.3M-10.4% | -$11.1M+6.2% | -$11.9M |
| Capital Expenditures | $0 | $0 | $0-100.0% | $981-80.5% | $5K-88.3% | $43K-80.9% | $224K-60.2% | $563K |
| Free Cash Flow | -$2.1M+14.2% | -$2.4M+58.6% | -$5.8M+19.9% | -$7.3M-20.7% | -$6.0M+51.0% | -$12.3M-8.6% | -$11.3M+8.7% | -$12.4M |
| Investing Cash Flow | $44K-91.7% | $523K | $0-100.0% | $3K+164.7% | -$5K+88.3% | -$43K+70.2% | -$143K-101.2% | $11.9M |
| Financing Cash Flow | $0-100.0% | $3.1M | $0 | $0 | $0 | $0 | $0-100.0% | $5.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NEXI Financial Ratios
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -334.1%-221.9pp | -112.2% | N/A | -119.4%-74.9pp | -44.5%-3.9pp | -40.6% | N/A | -30.9% |
| Return on Assets | -39.7%-5.5pp | -34.2% | N/A | -67.7%-35.4pp | -32.2%-1.0pp | -31.2% | N/A | -25.5% |
| Current Ratio | 0.66-0.6 | 1.30+0.2 | 1.06-0.6 | 1.66-1.3 | 2.95-0.8 | 3.74+0.1 | 3.62-1.9 | 5.54 |
| Debt-to-Equity | 7.10+4.9 | 2.20+2.2 | 0.00-0.8 | 0.76+0.4 | 0.38+0.1 | 0.30+0.3 | 0.00-0.2 | 0.21 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Neximmune, Inc. profitable?
No, Neximmune, Inc. (NEXI) reported a net income of -$32.3M in fiscal year 2023.
What is Neximmune, Inc.'s EBITDA?
Neximmune, Inc. (NEXI) had EBITDA of -$31.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Neximmune, Inc. have?
As of fiscal year 2023, Neximmune, Inc. (NEXI) had $3.2M in cash and equivalents against $0 in long-term debt.
What is Neximmune, Inc.'s return on equity (ROE)?
Neximmune, Inc. (NEXI) has a return on equity of -921.6% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What is Neximmune, Inc.'s free cash flow?
Neximmune, Inc. (NEXI) generated -$31.5M in free cash flow during fiscal year 2023. This represents a 40.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Neximmune, Inc.'s operating cash flow?
Neximmune, Inc. (NEXI) generated -$31.4M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Neximmune, Inc.'s total assets?
Neximmune, Inc. (NEXI) had $8.6M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Neximmune, Inc.'s capital expenditures?
Neximmune, Inc. (NEXI) invested $49K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Neximmune, Inc. spend on research and development?
Neximmune, Inc. (NEXI) invested $19.3M in research and development during fiscal year 2023.
What is Neximmune, Inc.'s current ratio?
Neximmune, Inc. (NEXI) had a current ratio of 1.06 as of fiscal year 2023, which is considered adequate.
What is Neximmune, Inc.'s debt-to-equity ratio?
Neximmune, Inc. (NEXI) had a debt-to-equity ratio of 0.00 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neximmune, Inc.'s return on assets (ROA)?
Neximmune, Inc. (NEXI) had a return on assets of -376.4% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Neximmune, Inc.'s cash runway?
Based on fiscal year 2023 data, Neximmune, Inc. (NEXI) had $3.2M in cash against an annual operating cash burn of $31.4M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Neximmune, Inc.'s Piotroski F-Score?
Neximmune, Inc. (NEXI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neximmune, Inc.'s earnings high quality?
Neximmune, Inc. (NEXI) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Neximmune, Inc.?
Neximmune, Inc. (NEXI) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.